TY - JOUR
T1 - Predictors of clinically significant quality of life impairment in Parkinson's disease
AU - Kulisevsky, Jaime
AU - Pascual-Sedano, Berta María
AU - Santos García, Diego
AU - de Deus Fonticoba, Teresa
AU - Cores Bartolomé, Carlos
AU - Muñoz, Guillermo
AU - Paz González, José M.
AU - Martínez Miró, Cristina
AU - Suárez, Ester
AU - Jesús, Silvia
AU - Aguilar Barberà, Miquel
AU - Pastor, Pau
AU - Planellas, Lluis
AU - Cosgaya, Marina
AU - García Caldentey, Juan
AU - Caballol, Nuria
AU - Legarda, Inés
AU - Hernández-Vara, Jorge
AU - Cabo-Lopez, Iria
AU - López Manzanares, Luis
AU - González Aramburu, Isabel
AU - Ávila, Asunción
AU - Catalán, Maria J.
AU - Nogueira, Víctor
AU - Puente, Víctor
AU - Ruíz de Arcos, María
AU - Borrué, Carmen
AU - Solano Vila, Berta
AU - Álvarez Sauco, María
AU - Vela, Lydia
AU - Escalante, Sonia
AU - Cubo, Esther
AU - Carrillo Padilla, Francisco
AU - Martínez-Castrillo, Juan Carlos
AU - Sánchez Alonso, Pilar
AU - Alonso Losada, Maria G.
AU - López Ariztegui, Nuria
AU - Gastón, Itziar
AU - Clavero, Pedro
AU - Blázquez Estrada, Marta
AU - Seijo, Manuel
AU - Rúiz Martínez, Javier
AU - Valero, Caridad
AU - Kurtis, Mónica
AU - Fàbregues-Boixar i Nebot, Oriol de
AU - González-Ardura, Jessica
AU - Ordás, Carlos
AU - López Díaz, Luis M.
AU - McAfee, Darrian
AU - Martinez-Martin, Pablo
AU - Mir, Pablo
AU - Adarmes, Daniela A.
AU - Almeria, Marta
AU - Alonso-Cánovas, Araceli
AU - Alonso Frech, Fernando
AU - Alonso Redondo, Rubén
AU - Álvarez, Ignacio
AU - Aneiros Díaz, Ángel
AU - Arnáiz, Sandra
AU - Arribas, Sonia
AU - Ascunce Vidondo, Arancha
AU - Bernardo Lambrich, Noemí
AU - Bejr-Kasem Marco, Helena
AU - Botí, M. Ángeles
AU - Buongiorno, María T.
AU - Cabello González, Carolina
AU - Cámara, Ana
AU - Canfield Medina, Héctor
AU - Carrillo, Fátima
AU - Casas, Elena
AU - Cortina Fernández, Ana
AU - Cots-Foraster, Anna
AU - Crespo Cuevas, Ane Miren
AU - Díez-Fairen, Mónica
AU - Dotor García-Soto, Julio
AU - Erro, Elena
AU - Estelrich Peyret, Elena
AU - Fernández Guillán, Noelia
AU - Gámez, Pedro
AU - Gallego, Miguel
AU - García Campos, Cristina
AU - García Moreno, José Manuel
AU - Gómez Garre, Maria P.
AU - Gómez Mayordomo, Víctor
AU - González Aloy, Javier
AU - González García, Beatriz
AU - González Palmás, Maria J.
AU - González Toledo, G.R
AU - Gabriel, R.
AU - Golpe Díaz, Ana
AU - Grau Solá, Mireia
AU - Guardia, Gemma
AU - Horta, Andrea
AU - Idoate Calderón, Daniel
AU - Infante, Jon
AU - Labandeira, Carmen
AU - Labrador-Espinosa, Miguel A
AU - Lacruz, Francisco
AU - Lage Castro, Melva
AU - Lastres Gómez, Sonia
AU - López Seoane, Balbino
AU - Lucas del Pozo, Sara
AU - Macías, Yolanda
AU - Mata, Marina
AU - Martí Andres, Gloria
AU - Martí, Maria J.
AU - Meitín, Maria T.
AU - Menéndez González, Manuel
AU - Méndez del Barrio, Carlota
AU - Miranda Santiago, Javier
AU - Morales Casado, null
AU - María, I.
AU - Moreno Diéguez, Antonio
AU - Novo Amado, Alba
AU - Novo Ponte, Sabela
AU - Pagonabarraga Mora, Javier
AU - Pareés, Isabel
AU - Pérez Fuertes, Aída
AU - Pérez Noguera, Rafael
AU - Planas-Ballvé, Ana
AU - Prats, Marian A.
AU - Prieto Jurczynska, Cristina
AU - Pueyo Morlans, Mercedes
AU - Puig-Davi, Arnau
AU - Redondo Rafales, Nuria
AU - Rodríguez Méndez, Luisa
AU - Rodríguez Pérez, Amparo B.
AU - Roldán, Florinda
AU - Sánchez-Carpintero, Macarena
AU - Sánchez Díez, Gemma
AU - Sánchez Rodríguez, Antonio
AU - Santacruz, Pilar
AU - Segundo Rodríguez, José C.
AU - Sierra Peña, María
AU - Tartari, Juan P.
AU - Vargas, Laura
AU - Villanueva, Clara
AU - Vives-Pastor, Bárbara
AU - Villar, María D.
PY - 2021
Y1 - 2021
N2 - Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.
AB - Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.
UR - https://www.scopus.com/pages/publications/85121519985
U2 - 10.1038/s41531-021-00256-w
DO - 10.1038/s41531-021-00256-w
M3 - Article
C2 - 34916528
SN - 2373-8057
VL - 7
JO - npj Parkinson's Disease
JF - npj Parkinson's Disease
IS - 1
ER -